Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, Heinz Feldmann, Michael A. Jarvis
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9a78a63a312847aa863ae1016f4d581a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9a78a63a312847aa863ae1016f4d581a

Ejemplares similares